Table 2b.
Subgroup | Placebo
|
Candesartan
|
||||
---|---|---|---|---|---|---|
Total | Primary, % | Secondary, % | Total | Primary, % | Secondary, % | |
A | 329 | 32 (27–37) | 12 (9–16) | 348 | 31 (26–36) | 11 (8–14) |
B | 125 | 33 (26–42) | 10 (6–17) | 134 | 28 (21–36) | 10 (6–16) |
C | 144 | 56 (48–64) | 36 (28–44) | 144 | 55 (47–64) | 29 (22–38) |
D | 317 | 39 (34–45) | 19 (15–24) | 287 | 33 (28–39) | 13 (10–18) |
E | 415 | 41 (36–46) | 17 (14–21) | 444 | 38 (34–43) | 15 (12–19) |
F | 175 | 54 (47–62) | 35 (28–43) | 157 | 53 (46–62) | 28 (22–37) |